CathWorks

Company Overview

Snapshot

Founded in February 2013 by Ifat Lavi and Guy Lavi, CathWorks operates with 51–200 employees. The company has raised over $151.79 million across 5 funding rounds from 9 investors. In February 2026, CathWorks was acquired by Medtronic.

Business overview

CathWorks is a medical technology company specializing in optimizing coronary artery disease (CAD) therapy decisions. The company's core product, the CathWorks FFRangio System, applies advanced computational science to provide objective, FFR-based decision-making tools for physicians, elevating coronary angiography from visual assessment. This system aims to offer quick, precise, and objective intraprocedural FFR guidance, serving the healthcare and life sciences sectors, particularly healthcare providers, with a focus on cardiology and diagnostics.

Strategic signal

In February 2026, CathWorks was acquired by Medtronic, a significant development that validates the company's innovative approach to cardiac diagnostics. This acquisition, following a co-promotion agreement in July 2022, signals a strong strategic alignment with a major medical device company, indicating a clear path for broader market penetration and integration of CathWorks' FFRangio System into mainstream cardiovascular care. For investors, this represents a successful exit and a strong endorsement of the company's technology and market potential.

Company Intelligence Q&A

What was the most significant recent corporate development for CathWorks?

In February 2026, CathWorks was acquired by Medtronic, a leading medical technology company. This acquisition followed a co-promotion agreement between the two companies announced in July 2022.

When did CathWorks receive FDA clearance for its FFRangio System?

The CathWorks FFRangio System received U.S. FDA 510(k) clearance in December 2018.

Which company led CathWorks' Series C funding round?

In February 2019, CathWorks announced the completion of a $30 million Series C funding round led by Deerfield Management.

When did CathWorks' FFRangio System receive regulatory approval in Japan?

The CathWorks FFRangio System received regulatory approval in Japan in December 2019, with a fourth-generation system also receiving approval in October 2022.

What was the purpose of the global ALL-RISE study announced by CathWorks?

In June 2023, CathWorks announced the enrollment of the first patient in its global ALL-RISE study, which aims to further evaluate the performance and utility of its FFRangio System.